This book provides BoNT treatment menus for symptom-oriented therapy in 14 different disease categories.Each chapter starts with a brief description of the disease and its current treatment followed by an evidenced-based upon the published assertions of the Therapeutic Subcommittee of the American Academy of Neurology. Each chapter includes case histories from editor's vast experience of over 25 years with BoNT therapy and description of injection techniques enhanced by illustrative figures. Botulinum Toxin Treatment in Clinical Medicine includes an additional introductory chapter that discusses molecular structure, mechanism of action, toxin serotypes, immunogenicity and safety issues. Meanwhile, a concluding chapter provides information on potential future application of these toxins' for treating symptoms of other specific diseases.

This practical collection examines methodologies originating from the benefits of genome-wide approaches to studying epigenetics, which has opened the emerging field of epigenomics. Focusing on the areas of cancer, inflammatory and autoimmune disorders, chapters discuss three main components of the epigenome and their role in the regulation of gene expression and present a detailed method section specific to studying each component, including data analyses, troubleshooting, and feasibility in different experimental settings. The main topics are high-throughput and targeted methods for DNA methylation analysis, nucleosome position mapping, studying epigenetic effects of gut microbiota, optical imaging for detection of epigenetic aberrations in living cells, methods for microRNA, and histone code profiling. Written for the Methods in Pharmacology and Toxicology series, the book includes the kind of detail and implementation advice to encourage success in the lab. Authoritative and easily applicable, Epigenetics and Gene Expression in Cancer, Inflammatory and Immune Diseases aims to provide pharmacologists, molecular biologists, bioinformaticians, and toxicologists with a vital background on epigenetics and state-of-the-art techniques in epigenomics.

The present monograph is devoted to the chemistry of nitroazoles, one of the most interesting series of heteroaromatic compounds. The azoles hold a special position in the chemistry of heterocycles. Their unique properties and specific biological activity attract much attention of research chemists all over the world. During the last years the interest in the chemistry of nitroazoles has increasing. The nitro derivatives of azoles have found a wide application in various fields of industrial chemistry, agriculture, and medicine. Medical products developed by nitroazoles incluce a- mycin, metronidazole, misonidazole, tinidazole, nitazole, etc. , ionic liquids, hi- energy materials, synthons for nanocompounds, universal bases in peptide nucleic acids, plant growth regulators, and intermediates for organic synthesis. The investigations in the field of energetic compounds have received enormous interest in recent years. Energetic materials on the base nitroazoles - explosives, propellants, and pyrotechnics - are widely used for both civilian and military applications. Nitroazoles, especially polynitroazoles, possess higher heat of for- tion, density, and oxygen balance than their carbocyclic analogs. A number of ongoing research programs worldwide are aimed for the development of new explosives and propellants with higher performance characteristics or enhanced insensitivity to thermal or shock insults and pyrotechnics with reduced smoke. The preparation of nitroazoles demonstrates its great synthetic potential. At the same time, feasibility and availability of the starting molecules make this strategy a p- erful method for high-energy material construction.

Adverse events in patients caused by medical management are a serious and grossly underreported public health problem. One patient in ten entering hospital will suffer an adverse event of impairment, disability or death. This book is a major comprehensive examination of the incidence and causes of adverse events. Using data obtained from hospitals within the United Kingdom, United States and other developed countries, it examines the risk factors leading to errors, the human and financial costs, and the scope to reduce errors. In particular, it focuses on the need for a critical reappraisal of undergraduate teaching and clinical tuition. All healthcare professionals throughout primary and secondary care, including clinicians, managers and policy makers, and patient and carer groups, can benefit from reading this book. It identifies possible solutions and how adverse events and medication errors can be reduced, resulting in improved patient care.

In light of the rising cost of healthcare and the overall challenges associated with delivering quality care to patients across regions, scientists and pharmacists are exploring new initiatives in drug discovery and design. One such initiative is the adoption of information technology and software applications to improve healthcare and pharmaceutical processes. Software Innovations in Clinical Drug Development and Safety is a comprehensive resource analyzing the integration of software engineering for the purpose of drug discovery, clinical trials, genomics, and drug safety testing. Taking a multi-faceted approach to the application of computational methods to pharmaceutical science, this publication is ideal for healthcare professionals, pharmacists, computer scientists, researchers, and students seeking the latest information on the architecture and design of software in clinical settings, the impact of clinical technologies on business models, and the safety and privacy of patients and patient data. This timely resource features a well-rounded discussion on topics pertaining to the integration of computational methods in pharmaceutical science and practice including, the impact of software integration on business models, patient safety concerns, software architecture and design, and data security.

Second comprehensive volume focuses on anti-inflammatory nutraceuticals and their role in prevention and therapy of various chronic diseases. Food and drug administration (FDA) approved drugs such as steroids, non-steroidal anti-inflammatory drugs (NSAIDS), statins and metformin have been shown to modulate inflammatory pathways, but their long-term intake has been associated with numerous side effects. Thus dietary agents which can modulate inflammatory pathways in humans, are likely to exhibit enormous potential. Leading experts describe the latest results of anti-inflammatory nutraceuticals and their role in prevention and therapy of various chronic diseases.

DNA Vaccines: An Introduction; M.R. Hilleman. Architecture of a DNA vaccine; G. Pavlakis. DNA vaccine delivery; S. Kaufmann. Adjuvanticity of DNA vaccines; A. Krieg. Immune responses to DNA vaccines: Antigen presentation; R. Steinman. Immune responses to DNA vaccines: Antigen processing; J. Yewdell. Immune responses to DNA vaccines: Induction of B cells; G. Kelsoe. Immune responses to DNA vaccines: Induction of CD4+ T cells; E. Shevach. Immune responses to DNA vaccines: Induction of CD8+ T cells; L. Whitton. Immune responses to DNA vaccines: Cytokines as immune mediators as part of the immune response and their potential as genetic adjuvants to DNA vaccines; H. Ertl. Immune responses to DNA vaccines: Chemokines as immune mediators as part of the immune response and their potential as genetic adjuvants to DNA vaccines; P. Murphy. DNA Vaccines to infectious agents: RNA viruses; J. Ulmer. DNA Vaccines to infectious agents: HIV/SIV; B. Wahren. DNA Vaccines to infectious agents: DNA viruses; B. Rouse. DNA Vaccines to infectious agents: Tumor-associated viruses (excluding HBV); R. Kennedy. DNA Vaccines to infectious agents: Bacteria; D. Lowrie. DNA Vaccines to infectious agents: Parasites; S. Hoffman. Use of DNA vaccines for neonatal/early childhood immunization; C.-A. Siegrist. The potential of DNA vaccines for developing countries; H. Wilde. DNA vaccines and their potential to counterbalance biological warfare/bioterrorism; A. Schmaljohn. DNA vaccines to cancer associated/specific antigens; DNA vaccines to autoimmune diseases; H. Wigzell. DNA vaccines to allergic diseases; Yan Chuah, P. Holt. DNA vaccines for gene therapy; K. High. Safety concerns for DNA; D. Klinman. DNA vaccines: Summary.

The International Symposia on Plant Lipids, the 15th of which was held in Okazaki, Japan, in May 12-17, 2002, is held every two years and is the only international meeting in this field. The contributions from the symposium collected in this book represent the most up-to-date research results on plant lipids,including their structure, analysis, biosynthesis, regulation, physiological function, environmental aspects, and biotechnology, obtained world-wide during 2000-2002.

A remarkable spectrum of novel immunoreceptors sharing related immunoglobulin-like domains and signaling potential has been identified in recent years. These receptors have attracted widespread interest because they resemble the TCR, BCR, and FcR complexes in their ability to serve as activating or inhibitory receptors on the cells that bear them. Moreover, they are well positioned to affect both innate and adaptive immunity. The full range of ligands for these new receptor families is still not known, and understanding of their physiological roles is far from complete. This volume is the first attempt to summarize and highlight all known aspects of immunoglobulin-like receptors, providing a topical overview of the roles and characteristic features of the immunoglobulin-like receptors and related molecules in the immune system. Researchers in immunology, molecular biology, cell biology, clinical medicine, and pharmacology will find this book invaluable.

This is an outstanding survey describing medical drugs of plant origin, such as Echinacea edications, lentinan and mistletoe lectin, which have proven to be effective as immunostimulants. At a time when ever greater importance is being placed on preventive and alternative medicine, the study provides the reader with information on the physiological mechanisms of action and range of application of phytopreparations capable of inducing immunostimulatory effects when administered prophylactically or therapeutically. "Immunomodulatory Agents from Plants" addresses scientists in the pharmaceutical industry; physicians - general practitioners, internists and oncologists - who work with traditional immunostimulants; and also pharmacists wishing to improve customer service by gaining a firmer understanding of the science underlying and the clinical facts associated with drugs presently on the market.

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.

Personalized medicine, which simply means selection of treatment best suited for an individual, involves integration and translation of several new technologies in clinical care of patients. The scope is much broader than indicated by the term genomic medicine because many non-genomic factors are taken into consideration in developing personalized medicine. Basic technologies for personalized medicine, of which molecular diagnostics has the biggest share, are mentioned briefly and appropriate references are given for further information. Commercial aspects are discussed briefly in a chapter and detailed analysis of markets and companies involved in personalized medicine is presented in a special report on this topic.

There is increasing interest in personalized medicine. Considerable advances have taken place in molecular biology and biotechnology to make personalized medicine a viable option, but some misconceptions still exist, both in the academic and commercial sectors. There is lack of a suitable source of information that provides both the fundamentals as well as applications of personalized medicine. As the latest version of the first monograph on personalized medicine published in 1998, this volume, Textbook of Personalized Medicine, summarizes the author's efforts during the past decade, as well as reviews selected studies done during this period in a readable format for the physicians and scientists. It is hoped that physicians, pharmacists, scientists and interested lay readers with basic scientific knowledge will find this book useful.

In recent years it has become clear that early information about pharmacodynamics leads to more efficient trial designs and improved clinical guidelines for the use of all drugs. Spanning many of the major drug classes, this book offers the essential facts and concepts and includes an authoritative section on general methodology and regulatory issues. The molecular biology and pharmacology of major receptor types are considered, as is the detailed pharmacodynamics of a wide range of therapeutic drug classes. The book will be of interest to researchers, clinical pharmacologists, physicians and regulators working in academia as well as the pharmaceutical industry worldwide.

Dieser Band des Gebietes Stoffe enthAlt in alphabetischer Reihenfolge als ErgAnzung zum Hauptwerk Monographien A1/4ber Arzneistoffe, Hilfsstoffe, Impfstoffe und Sera sowie Reagenzien. In den Monographien werden Aussagen A1/4ber die Synthese, die Eigenschaften, die Erkennung, die Reinheit, den Gehalt, die Wirkung und die medizinische Anwendung gemacht. Von besonderer Bedeutung sind Stoffe des DAB und von in Europa gA1/4ltigen ArzneibA1/4chern.

This volume is the proceedings of the 4th International Conference on Cognitive Neurodynamics (ICCN2013) held in Sweden in 2013. The included papers reflect the large span of research presented and are grouped in ten parts that are organized essentially in a top-down structure. The first parts deal with social/interactive (I) and mental (II) aspects of brain functions and their relation to perception and cognition (III). Next, more specific aspects of sensory systems (IV) and neural network dynamics of brain functions (V), including the effects of oscillations, synchronization and synaptic plasticity (VI), are addressed, followed by papers particularly emphasizing the use of neural computation and information processing (VII). With the next two parts, the levels of cellular and intracellular processes (VIII) and finally quantum effects (IX) are reached. The last part (X) is devoted to the contributions invited by the Dynamic Brain Forum (DBF), which was co-organized with ICCN2013.

The book presents the current state of the art on phytocannnabinoid chemistry and pharmacology and will be of much use to those wishing to understand the current landscape of the exciting and intriguing phytocannabinoid science. The focus is on natural product cannabinoids which have been demonstrated to act at specific receptor targets in the CNS.

A fresh examination of the past successes of natural products as medicines and their new future from both conventional and new technologies. High-performance liquid chromatography profiling, combinatorial synthesis, genomics, proteomics, DNA shuffling, bioinformatics, and genetic manipulation all now make it possible to rapidly evaluate the activities of extracts as well as purified components derived from microbes, plants, and marine organisms. The authors apply these methods to new natural product drug discoveries, to microbial diversity, to specific groups of products (Chinese herbal drugs, antitumor drugs from microbes and plants, terpenoids, and arsenic compounds), and to specific sources (the sea, rainforest, and endophytes). These new opportunities show how research and development trends in the pharmaceutical industry can advance to include both synthetic compounds and natural products, and how this paradigm shift can be more productive and efficacious.

Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.

This dictionary provides a convenient personal reference source, intended to complement more encyclopaedic works. First, there is an alphabetic, fully cross-indexed listing of pharmacologically active agents and their properties, containing details of some 4000 individual chemical agents including medical drugs in current use, experimental agents and toxins used as investigation tools. Over 10,000 alternative names are indexed, including chemical names, abbreviated chemical names, official pharmacological names, proprietary names and research code numbers. A key feature is that the properties of the agents are categorised, according to mechanism and use, into 300 classes -for each of which there are descriptive articles for which key literature and review references are provided. Second, there is an alphabetical glossary explaining the meaning of some 3000 biomedical terms from pharmacology, biochemistry, molecular biology, immunology, pathology, physiology, anatomy and microbiology. Emphasis in explanation is given to terms that can cause confusion, for example those relating to drug receptors and to endogenous mediators. Audience: This work provides indispensable information for researchers in the fields of pharmacology, medicinal chemistry and pharmaceutics, and biochemistry, as well as for medical and science writers and editors and drug regulatory officers.

This volume describes our current understanding of the biological role of the delta-opioid receptor (DOR) system, focusing on its unique mechanisms of receptor trafficking and signaling in disease states. Part 1 covers the endogenous ligands that regulate the DOR system as well as novel compounds and therapies used to modulate the DOR system. Part 2 describes new insights into the localization and trafficking of the DOR and how ligand-directed signaling alters the fate of the receptor. Part 3 concentrates on the potential role of the DOR system in disease states, such as pain, mood, addiction, and Parkinson's disease. Throughout the book, the DOR system as a target for drug development will be discussed.

The ambitious goal of this volume is to provide in chapters written by accomplished scientists and experts in their field a comprehensive overview of the currently available information related to the therapeutic utility of adult bone marrow-derived cells. With excitement generated almost daily about the possible uses of stem cells to treat human disease, but the controversy surrounding their use still raging, adult bone-marrow derived cells are more readily available, and have a staggering range of uses.

Polluted air and contaminated food and water are major causes of human health deterioration, but public health policy has long struggled to effectively address these concerns. This timely book--written for a wide audience of policy makers, researchers, and general readers--synthesizes what we already know about environmental hazards, identifies the gaps in our knowledge, and provides a roadmap for reducing human exposure to environmental pollution. With contributions from leading experts, Environmental Determinants of Human Health examines numerous pollutants, both inorganic and organic, in the context of their human health impacts. Individual chapters explore exposure pathways, macroeconomic impacts of human health deterioration, technological and non-technological methods for reducing exposures, monetary and non-monetary benefits from exposure reduction, and risk communication and awareness, including citizen participation approaches. This volume is a crucial text for policy makers requiring scientific justification for the development of new environmental regulations, scientists researching public health and environmental contamination, and members of the public interested in human health issues.

Dr. Myrtle A. Davis has assembled a panel of cutting-edge scientists to describe their best methods for detecting, illuminating, and quantifying apoptotic mechanisms in a way that is useful for the design of toxicology and pharmacology studies. These state-of-the-art techniques include flow cytometric, fluorometric, and laser scanning methods for quantifying and characterizing apoptosis, as well as protocols for the use of DNA microarray technology, high throughput screens, and ELISA. Immunocytochemical methods for measuring biochemical and molecular endpoints in tissue sections will be highly useful for those carrying out studies in whole animal models as opposed to cell culture systems.

Progress in Drug Research is a prestigious book series which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmacological research. It serves as an important source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.

The over-arching goal of this volume is to help infertility practitioners evaluate and manage their patients with poor semen quality. The authors review the existing literature on the effects of medications on male fertility, and provide detailed information about what is known, giving the number of individuals and population characteristics for studies of medication effects on male fertility. Medications are designed to treat illness and reduce symptoms, but all have undesirable adverse effects such as headache or stomach upset. Some adverse reactions can even be life-threatening, so it is no surprise that some drugs have negative effects on male reproduction. Medical practitioners rarely consider a man's reproductive plans when prescribing medications. Men are routinely treated with drugs that can impair or abolish fertility. Although practitioners in the field of reproductive medicine generally realize that certain drugs impact negatively on reproductive health, there are limited resources providing evidence-based knowledge useful in counseling patients. Tables throughout this volume summarize the information for each drug, providing a handy reference for clinical use.